Effects of HAART on platelet-activating factor metabolism in naive HIV-infected patients I: Study of the tenofovir-DF/emtricitabine/efavirenz HAART regimen

AIDS Research and Human Retroviruses

Volumn 28, Issue 8, 2012, Pages 766-775

  Chini, Maria ^a   Tsoupras, Alexandros B ^b   Mangafas, Nikos ^a   Tsogas, Nikos ^a   Papakonstantinou, Vasiliki D ^b   Fragopoulou, Elizabeth ^c   Antonopoulou, Smaragdi ^c   Gargalianos, Panagiotis ^d   Demopoulos, Constantinos A ^b   Lazanas, Marios C ^a  

^a RED CROSS HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c HAROKOPIO UNIVERSITY   (Greece)

^d G GENNIMATAS GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; BIOCHEMICAL MARKER; CHOLINEPHOSPHOTRANSFERASE; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; PHOSPHOLIPASE A2; THROMBOCYTE ACTIVATING FACTOR;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CORRELATION COEFFICIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE; MALE; NONHUMAN; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; STATISTICAL MODEL; VIRUS LOAD;

ADENINE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DEOXYCYTIDINE; DRUG COMBINATIONS; HIV INFECTIONS; HUMANS; MALE; ORGANOPHOSPHONATES; OXAZINES; PLATELET ACTIVATING FACTOR; VIRAL LOAD;

EID: 84864214245     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0202     Document Type: Article

References (32)

1. Demopoulos CA, Pinckard RN, and Hanahan DJ: Plateletactivating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl- 3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J Biol Chem 1979;254:9355-9358.
2. Honda Z, Ishii S, and Shimizu T: Platelet-activating factor receptor. J Biochem 2002;131:773-779.
3. Zimmerman GA, McIntyre TM, Prescott SM, et al.: The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med 2002;30:294-301.
4. Snyder F: Platelet-activating factor and its analogs: Metabolic pathways and related intracellular processes. Biochim Biophys Acta 1995;1254:231-249.
5. Francescangeli E, Boila A, and Goracci G: Properties and regulation of microsomal PAF-synthesizing enzymes in rat brain cortex. Neurochem Res 2000;25:705-713.
6. Snyder F: CDP-choline:alkylacetylglycerol cholinephosphotransferase catalyzes the final step in the De novo synthesis of platelet-activating factor. Biochim Biophys Acta 1997; 1348:111-116.
7. Stafforini DM, McIntyre TM, Carter ME, et al.: Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor. J Biol Chem 1987;262:4215-4222.
8. Montrucchio G, Alloatti G, and Camussi G: Role of plateletactivating factor in cardiovascular pathophysiology. Physiol Rev 2000;80:1669-1699.
9. Demopoulos CA, Karantonis HC, and Antonopoulou S: Platelet activating factor-a molecular link between atherosclerosis theories. Eur J Lipid Sci Technol 2003;105:705-716.
10. Iatrou C, Moustakas G, Antonopoulou S, et al.: Plateletactivating factor levels and PAF acetylhydrolase activities in patients with primary glomerulonephritis. Nephron 1996;72: 611-616.
11. McManus LM and Pinckard RN: PAF, a putative mediator of oral inflammation. Crit Rev Oral Biol Med 2000;11:240-258.
12. Kasperska-Zajac A, Brzoza Z, and Rogala B: Platelet-activating factor (PAF): A review of its role in asthma and clinical efficacy of PAF antagonists in the disease therapy. Recent Pat Inflamm Allergy Drug Discov 2008;2:72-76.
13. Nathan N, Denizot Y, Huc MC, et al.: Elevated levels of pafacether in blood of patients with type 1 diabetes mellitus. Diabete Metab 1992;18:59-62.
14. Tsoupras AB, Iatrou C, Frangia C, et al.: The implication of platelet activating factor in cancer growth and metastasis: Potent beneficial role of PAF-inhibitors and antioxidants. Infect Disord Drug Targets 2009;9:390-399.
15. Doublier S, Zennaro C, Spatola T, et al.: HIV-1 Tat reduces nephrin in human podocytes: A potential mechanism for enhanced glomerular permeability in HIV-associated nephropathy. AIDS 2007;21:423-432.
16. Perry SW, Hamilton JA, Tjoelker LW, et al.: Platelet-activating factor receptor activation. An initiator step in HIV-1 neuropathogenesis. J Biol Chem 1998;273:17660-17664.
17. Biancone L, Cantaluppi V, Boccellino M, et al.: Motility induced by human immunodeficiency virus-1 Tat on Kaposi's sarcoma cells requires platelet-activating factor synthesis. Am J Pathol 1999;155:1731-1739.
18. Martin M, Serradji N, Dereuddre-Bosquet N, et al.: PMS-601, a new platelet-activating factor receptor antagonist that inhibits human immunodeficiency virus replication and potentiates zidovudine activity in macrophages. Antimicrob Agents Chemother 2000;44:3150-3154.
19. Tsoupras AB, Chini M, Tsogas N, et al.: Anti-plateletactivating factor effects of highly active antiretroviral therapy (HAART): A new insight in the drug therapy of HIV infection? AIDS Res Hum Retroviruses 2008;24:1079-1086.
20. Negro Alvarez JM, Miralles López JC, Ortiz Martínez JL, et al.: Platelet-activating factor antagonists. Allergol Immunopathol 1997;25:249-258.
21. Feuerstein G, Rabinovici R, Leor J, et al.: Platelet-activating factor and cardiac diseases: Therapeutic potential for PAF inhibitors. J Lipid Mediat Cell Signal 1997;15:255-284.
22. Tsoupras AB, Chini M, Tsogas N, et al.: Platelet activating factor and its basic metabolic enzymes in blood of naïve HIV-infected patients. Angiology 2011;Manuscript ID ANG- 11-06-161.
23. Bradford MM: A rapid and sensitive method for the quantization of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
24. Tsoupras AB, Fragopoulou E, Nomikos T, et al.: Characterization of the De novo biosynthetic enzyme of platelet activating factor, DDT-insensitive cholinephosphotransferase, of human mesangial cells. Mediators Inflamm 2007; 2007:27683.
25. Bligh EG and Dyer WJ: A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37:911-917.
26. Antonopoulou S, Demopoulos CA, Iatrou C, et al.: Plateletactivating factor acetylhydrolase (PAF-AH) in human kidney. Int J Biochem 1994;26:1157-1162.
27. Tsoupras AB, Chini M, Tsongas N, et al.: In vivo effects of a Ginkgo biloba extract on platelet activating factor metabolism in two asymptomatic HIV-infected patients. Eur J Inflam 2011;9:107-117.
28. Shindou H, Hishikawa D, Nakanishi H, et al.: A single enzyme catalyzes both platelet-activating factor production and membrane biogenesis of inflammatory cells. Cloning and characterization of acetyl-CoA:lyso-PAF acetyltransferase. J Biol Chem 2007;282:6532-6539.
29. Khovidhunkit W, Memon RA, Shigenaga JK, et al.: Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Metabolism 1999;48:1524-1531.
30. Carlquist JF, Muhlestein JB, and Anderson JL: Lipoproteinassociated phospholipase A2: A new biomarker for cardiovascular risk assessment and potential therapeutic target. Expert Rev Mol Diagn 2007;7:511-517.
31. Dulioust A, Vivier E, Salem P, et al.: Immunoregulatory functions of paf-acether. I. Effect of paf-acether on CD4 + cell proliferation. J Immunol 1988;140:240-245.
32. Dulioust A, Duprez V, Pitton C, et al.: Immunoregulatory functions of paf-acether. III. Down-regulation of CD4 + T cells high-affinity IL-2 receptor expression. J Immunol 1990;144:3123-3129.